FDA approves psilocybin-based orphan drug for Fragile X syndrome

Written by Darcy Hodge, Editor

Psilocybin

The FDA has approved a new development by Nova Mentis Life Science (Vancouver, Canada). The biotechnology company has developed a psilocybin-based drug in order to treat Fragile X syndrome, implicated to have links to autism spectrum disorder. The biotech company aims to develop diagnostics and psilocybin-based therapeutics for disorders that are yet to find appropriate treatments. This includes conditions such as Fragile X syndrome, autism spectrum disorder and comorbid depression. The approval positions Nova Mentis Life Science in a unique position for biotechs, due to established leadership within the field of psychedelic therapy. It is thought that the non-toxic psilocybin...

To view this content, please register now for access

It's completely free